NEWS & EVENTS

Catalent today announced that it has completed the installation and commissioning of four new high throughput ‘high-bay’ CGMP manufacturing suites at its facility in Kansas City, Missouri, to increase its capacity and capabilities for producing oral solid dose forms.

Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.

Dr. Cedrone will collaborate closely with Catalent’s scientific teams and external partners to leverage innovative technologies in the development of emerging therapeutic modalities.

Catalent today announced the completion of a $30 million project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.

The report is the third since Catalent launched its CR strategy to address a wide range of environmental, social, and governance (ESG) topics related to its business.

Catalent today announced that company experts will be speaking on current clinical market trends and strategies at two upcoming conferences: Clinical Trial Supply New England; and Clinical Trial Supply Europe.

TFF Pharmaceuticals and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics.

Catalent today announced that it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2022 in both the United States and the United Kingdom.